Related Experiment Video
Updated: Jan 16, 2026
An Improved and High Throughput Respiratory Syncytial Virus RSV Micro-neutralization Assay
Published on: January 26, 2019
Advances in RSV Immunoprophylaxis: Evolution, Efficacy, and Implementation Challenges
Faris Al Gharaibeh1,2, Ved Deshmukh2, Hitesh Deshmukh1,2
1Division of Neonatology, Cincinnati Children's Hospital Medical Center, Cincinnati, Ohio.
Insights
New respiratory syncytial virus (RSV) prevention strategies, including advanced antibodies and maternal vaccines, show over 70% efficacy in reducing infant hospitalizations. Implementation requires addressing global access and healthcare delivery challenges.
Area of Science:
- Pediatrics
- Infectious Diseases
- Public Health
Background:
- Respiratory syncytial virus (RSV) causes significant global mortality and morbidity in young children, particularly infants under 12 months.
- The disease places a substantial burden on global healthcare systems, necessitating effective prevention strategies.
- Infants under 12 months bear a disproportionate burden of RSV infections and associated mortality.
Purpose of the Study:
- To review the evolution and current state of RSV prevention strategies.
- To evaluate the efficacy and implementation challenges of novel RSV interventions.
- To explore future directions for RSV prevention, considering global access and climate change.
Main Methods:
- Comprehensive literature review of evidence-based guidelines and clinical trial data.
- Analysis of economic evaluations for RSV prevention interventions.
- Exploration of implementation challenges, including healthcare delivery and global equity.
Main Results:
- Next-generation monoclonal antibodies and novel vaccination approaches in pregnant individuals demonstrate over 70% efficacy in reducing RSV-associated hospitalizations.
- Economic analyses indicate favorable cost-benefit ratios for current prevention strategies.
- Implementation necessitates careful consideration of healthcare delivery systems and equitable global access.
Conclusions:
- Recent advances in RSV prevention offer unprecedented efficacy, significantly reducing disease burden in infants.
- Successful global implementation hinges on addressing healthcare system capacities and ensuring equitable access to interventions.
- Future strategies must also consider emerging challenges, such as climate change impacts on RSV seasonality.
Abstract:
Respiratory syncytial virus (RSV) poses a critical global health challenge, causing more than 33.1 million acute lower respiratory tract infections and more than 118 000 deaths annually in children younger than 5 years of age. The burden falls disproportionately on infants younger than 12 months of age, with devastating impacts on health care systems worldwide. Prevention strategies have evolved from early vaccine attempts through first-generation monoclonal antibodies to current next-generation antibodies with extended half-lives and novel vaccination approaches in pregnant persons. These recent advances demonstrate unprecedented efficacy, with clinical trials showing reduction rates exceeding 70% in RSV-associated hospitalizations across diverse infant populations. Although economic analyses suggest favorable cost-benefit ratios, implementation raises important considerations regarding health care delivery systems and global access equity. This comprehensive review synthesizes evidence-based guidelines, evaluates implementation challenges, and explores future directions for RSV prevention, with particular attention to regional variations in health care delivery and emerging challenges from changing climate patterns affecting RSV seasonality.
